Scarica l'app Stockscreener
16.15
1.33%
0.36
Precedente Chiudi:
$15.79
Aprire:
$15.69
Volume 24 ore:
11,008
Relative Volume:
0.03
Capitalizzazione di mercato:
$881.19M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+42.98%
1M Prestazione:
+34.00%
6M Prestazione:
+26.38%
1 anno Prestazione:
-34.51%
Intervallo 1D:
$15.55
$16.15
Intervallo di 1 settimana:
$10.48
$16.00
Portata 52W:
$7.80
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Nome
Bicara Therapeutics Inc
Settore
Industria
Telefono
617-468-4219
Indirizzo
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Confronta BCAX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
16.15 | 756.79M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.21 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.49 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
455.80 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
770.31 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.16 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-05-23 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | Iniziato | Wells Fargo | Underweight |
| 2025-02-06 | Iniziato | Wedbush | Outperform |
| 2024-12-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-05 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Iniziato | Morgan Stanley | Overweight |
| 2024-10-08 | Iniziato | Stifel | Buy |
| 2024-10-08 | Iniziato | TD Cowen | Buy |
Mostra tutto
Bicara Therapeutics Inc Borsa (BCAX) Ultime notizie
Key metrics from Bicara Therapeutics Inc.’s quarterly dataWeekly Trade Report & Weekly Breakout Opportunity Watchlist - newser.com
Stifel maintains Buy on Bicara stock with $47 target - MSN
Bicara Therapeutics stock rating reiterated as Buy by TD Cowen - Investing.com India
Promising Market Opportunity for Bicara Therapeutics in HPV-Negative Head & Neck Cancer Warrants Buy Rating - TipRanks
What analysts say about Bicara Therapeutics Inc stockTrend Following Strategies & Big Profit Small Investment - earlytimes.in
Statistical indicators supporting Bicara Therapeutics Inc.’s strengthWeekly Investment Summary & High Conviction Buy Zone Alerts - newser.com
Brokerages Set Bicara Therapeutics Inc. (NASDAQ:BCAX) PT at $32.25 - Defense World
How to read the order book for Bicara Therapeutics Inc.Trade Risk Summary & Real-Time Chart Pattern Alerts - newser.com
Can Bicara Therapeutics Inc. stock resist sector downturnsJuly 2025 Final Week & Expert Approved Trade Ideas - newser.com
Optimistic Buy Rating for Bicara Therapeutics: Superior Clinical Benefits and Valuation Upside - TipRanks
What drives Bicara Therapeutics Inc stock priceMACD Histogram Signals & Calculate Profit Targets With AI Accuracy - earlytimes.in
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Up 7.8%Here's What Happened - MarketBeat
Atle Fund Management AB Acquires 27,547 Shares of Bicara Therapeutics Inc. $BCAX - MarketBeat
Analyzing recovery setups for Bicara Therapeutics Inc. investors2025 Institutional Moves & AI Powered Buy and Sell Recommendations - newser.com
Is Bicara Therapeutics Inc. stock reversal real or fakeMarket Performance Recap & Weekly Stock Performance Updates - newser.com
Bicara Therapeutics (NASDAQ:BCAX) Trading Down 5.5%Time to Sell? - MarketBeat
Using flow based indicators on Bicara Therapeutics Inc.New Guidance & Intraday High Probability Alerts - newser.com
Revenue Check: Will Bicara Therapeutics Inc. benefit from current market trends2025 Major Catalysts & Reliable Price Action Trade Plans - خودرو بانک
Risks Report: What makes Q32 Bio Inc. stock attractive todayJuly 2025 Catalysts & Expert Curated Trade Setup Alerts - khodrobank.com
What does recent volatility data suggest for Bicara Therapeutics Inc.Trade Ideas & Verified Entry Point Detection - newser.com
Is a relief rally coming for Bicara Therapeutics Inc. holdersJuly 2025 Analyst Calls & Technical Entry and Exit Alerts - newser.com
Is Bicara Therapeutics Incs growth already priced inMarket Sentiment Report & High Yield Stock Recommendations - خودرو بانک
What is Bicara Therapeutics Incs revenue forecastTrade Volume Report & Free Long-Term Investment Growth Plans - خودرو بانک
Volatility Watch: How cyclical is Bicara Therapeutics Incs revenue streamQuarterly Performance Summary & Entry and Exit Point Strategies - خودرو بانک
Rate Cut: What is Bicara Therapeutics Incs revenue forecastJuly 2025 Patterns & Long-Term Capital Growth Strategies - khodrobank.com
CEO Change: Is Bicara Therapeutics Inc.’s growth already priced inMarket Sentiment Summary & Weekly Top Gainers Alerts - khodrobank.com
Technical analysis overview for Bicara Therapeutics Inc. stock2025 Buyback Activity & Safe Capital Growth Stock Tips - newser.com
Is Atmus Filtration Technologies Inc stock a buy or sellJuly 2025 Big Picture & Entry Point Strategy Guides - khodrobank.com
Risk Off: What is Bicara Therapeutics Incs market position2025 Price Action Summary & Low Risk High Win Rate Picks - خودرو بانک
Bicara Therapeutics Inc Azioni (BCAX) Dati Finanziari
Non sono disponibili dati finanziari per Bicara Therapeutics Inc (BCAX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.35%
0.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):